Shares surged 20% to $111.55 in after-hours trading after Corcept Therapeutics crushed second-quarter expectations and raised full-year 2026 revenue guidance to $1.1–$1.2 billion, a sharp jump from the $950 million–$1.05 billion range set just three months ago. For a company that had been drifting sideways—and was downgraded days earlier—the beat is a direct rebuke to the bears.
A Cancer Drug Launch That's Running Ahead of Schedule. The FDA approved Lifyorli in March 2026 for women with platinum-resistant ovarian cancer , and in April it was added to national cancer treatment guidelines as a preferred regimen, with uptake described as "vigorous."
Wolfe Research, which had just downgraded the stock to Underperform with a $50 target, itself expected Lifyorli sales to exceed the "low" Q2 bar. The actual beat—strong enough to lift full-year guidance by roughly $100–$150 million—suggests oncologists are prescribing the drug faster than Wall Street modeled. That kind of early momentum matters because it signals sustainable demand, not one-time stocking.
The Core Business Is Still Growing, Not Fading. Before Q2, Corcept was essentially a one-product company. Korlym, its Cushing's syndrome drug, hit $164.9 million in Q1 revenue, with March and April marking all-time highs in patients starting treatment.
Management targets at least $2 billion in annual Cushing's revenue by decade-end. The guidance raise signals that neither generic competition fears nor a pharmacy vendor transition have dented that franchise.
The Profit Swing Is the Underappreciated Story. Corcept reported a net loss of $0.30 per share in Q1 due to launch spending, but management promised a return to profitability in Q2. Delivering on that pledge—while also beating on revenue—shows the heavy investment phase is yielding returns, not just burning cash. The company held $515.4 million in cash at the end of Q1 , giving it ample runway for ongoing trials in ALS and liver disease.
The Valuation Debate Starts Now. At $111.55, CORT trades at a steep premium to where Canaccord's $150 target and Wolfe's $50 target bracket the bull-bear spectrum. The stock has roughly tripled from its early-2026 lows. If the full-year guidance midpoint of $1.15 billion holds, investors are paying around 10x forward revenue—expensive for pharma, but potentially justified if Lifyorli's cancer franchise scales toward management's goal of $1 billion-plus in annual U.S. oncology sales by the end of the decade. The open question: how much good news is already priced in?